Gastroenteropancreatic and Thoracic Neuroendocrine Tumors: Cabozantinib and Lanreotide Study

We are studying the safety and effectiveness of a new combination treatment for patients with gastroenteropancreatic and thoracic neuroendocrine tumors. This trial aims to find out if this combination can improve treatment outcomes compared to current options.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Cabozantinib Ipsen
Cabozantinib Ipsen is a cancer medicine used to treat certain advanced kidney, liver, and thyroid cancers.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Cabozantinib
Cabozantinib is a substance used to treat certain advanced cancers by blocking signals that help tumors grow and spread.
Lanreotide
Lanreotide is a somatostatin analogue used to treat acromegaly and control symptoms of neuroendocrine tumors.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Cabometyx
Cometriq

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
Interdisciplinary Medicine
Bari, Italy
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
Medical Oncology
Beinasco, Italy
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
Medical Oncology
Bologna, Italy

Sponsor: Fondazione IRCCS Istituto Nazionale Dei Tumori
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.